Role of RKIP in Inflammatory Responses

Wenlong Lin,Xiaojian Wang

DOI: https://doi.org/10.1016/b978-0-12-819612-0.00017-1

2020-01-01

Abstract:Raf kinase inhibitor protein (RKIP) is well known as an important suppressor in oncology; however, the function of RKIP in the immune response remains unclear. In this review, we will discuss the regulatory role of RKIP in immune cells and non-immune cells mediated inflammation.

What problem does this paper attempt to address?

Rkip Mediates Autoimmune Inflammation By Positively Regulating Il-17r Signaling

Wenlong Lin,Ning Wang,Kangxing Zhou,Fasheng Su,Yu Jiang,Jianan Shou,Huan Liu,Chunmei Ma,Youchun Qian,Kai Wang,Xiaojian Wang

DOI: https://doi.org/10.15252/embr.201744951

IF: 9.071

2018-01-01

EMBO Reports

Abstract:Th17 cells contribute to the development of autoimmune diseases by secreting interleukin-17 (IL-17), which activates its receptor (IL-17R) that is expressed on epithelial cells, macrophages, microglia, and resident neuroectodermal cells. However, the mechanisms through which IL-17R-mediated signaling contributes to the development of autoimmune disease have not been completely elucidated. Here, we demonstrate that Raf-1 kinase inhibitor protein (RKIP) deficiency in mice ameliorates the symptoms of experimental autoimmune encephalomyelitis (EAE). Adoptive T-cell-transfer experiments demonstrate that RKIP plays a predominant role in Th17-mediated, but not in Th1-mediated immune responses. RKIP deficiency has no effect on Th17-cell differentiation ex vivo, nor does it affect Th17-cell differentiation in EAE mice. However, RKIP significantly promotes IL-17R-induced proinflammatory cytokine and chemokine production. Mechanistically, RKIP directly interacts with IL-17RA and Act1 to promote the formation of an IL-17R-Act1 complex, resulting in enhanced MAPK- and P65-mediated NF-B activation and downstream cytokine production. Together, these findings indicate that RKIP functions as an essential modulator of the IL-17R-Act1 axis in IL-17R signaling, which promotes IL-17-induced inflammation and autoimmune neuroinflammation.
Raf Kinase Inhibitor Protein Preferentially Promotes Tlr3-Triggered Signaling and Inflammation

Rongrong Lai,Meidi Gu,Wei Jiang,Wenlong Lin,Penglei Xu,Zhiyong Liu,He Huang,Huazhang An,Xiaojian Wang

DOI: https://doi.org/10.4049/jimmunol.1601672

2017-01-01

Abstract:Raf kinase inhibitor protein (RKIP) protects against host immunological responses in nematodes and Drosophila. Whether RKIP functions in innate immune responses in mammals remains unknown. In this article, we report that RKIP preferentially regulates the TLR3-mediated immune response in macrophages. RKIP deficiency or silencing significantly decreases polyinosinic: polycytidylic acid [Poly(I:C)]-induced IFN-beta, IL-6, and TNF-alpha production without affecting the counterpart induced by LPS or CpG. Compared with their wild-type counterparts, RKIP-deficient mice produce less IFN-beta, IL-6, and TNF-alpha in serum and display decreased lethality upon peritoneal Poly(I:C) plus D-galactosamine injection. Mechanistically, RKIP interacts with TBK1 and promotes the Poly(I:C)-induced TANK-binding kinase 1/IRF3 activation. Simultaneously, RKIP enhances the Poly(I:C)-induced interaction between TGF-beta-activated kinase 1 and MAPK kinase 3 (MKK3), thus promoting MKK3/6 and p38 activation. We further demonstrated that Poly(I:C) treatment, but not LPS treatment, induces RKIP phosphorylation at S109. This action is required for RKIP to promote TANK-binding kinase 1 activation, as well as the interaction between TGF-beta-activated kinase 1 and MKK3, which lead to activation of the downstream IRF3 and p38, respectively. Therefore, RKIP acts as a positive-feedback regulator of the TLR3-induced inflammatory response and may be a potential therapeutic target for inflammatory disease.
Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice

Wenlong Lin,Chunmei Ma,Fasheng Su,Yu Jiang,Rongrong Lai,Ting Zhang,Kai Sun,Liping Fan,Zijian Cai,Zhongqi Li,He Huang,Jun Li,Xiaojian Wang

DOI: https://doi.org/10.1136/gutjnl-2015-310096

IF: 24.5

Gut

Abstract:Objective: Raf kinase inhibitor protein (RKIP) appears to control cancer cell metastasis and its expression in colonic tissue is related to colonic cancer development. We sought to identify the roles of RKIP in maintaining homeostasis of GI tract. Design: The expression of RKIP was determined by immunohistochemistry and western blot analysis. RKIP knockout and wild-type mice were administered dextran sulfate sodium (DSS) or 2,4,6-trinitrobenzenesulfonic acid (TNBS) to induce experimental colitis, and the mice were assessed based on colitis symptoms and biochemical approaches. The mechanism was analysed using immunoprecipitation and pull-down experiments. Results: The RKIP expression is positively correlated with the severity of IBD. RKIP deficiency protects mice from DSS-induced or TNBS-induced colitis and accelerated recovery from colitis. RKIP deficiency inhibits DSS-induced infiltration of acute-phase immune cells and reduces production of proinflammatory cytokines and chemokines in colon. RKIP deficiency inhibits DSS-induced or TNBS-induced colonic epithelial barrier damage and intestinal epithelial cell (IEC) apoptosis. RKIP deficiency also inhibits tumour necrosis factor-alpha-induced IEC apoptosis and colitis. Mechanistically, RKIP enhances the induction of P53-upregulated modulator of apoptosis by interacting with TGF-β-activated kinase 1 (TAK1) and promoting TAK1-mediated NF-κB activation. This is supported by the observation that TAK1 activation is positively correlated with the expression of RKIP in human clinical samples and the development of IBD. Conclusions: RKIP contributes to colitis development by promoting inflammation and mediating IEC apoptosis and might represent a therapeutic target of IBD.
Regulation role of Raf kinase inhibitory protein to mitogen-activated protein kinase signaling pathway

LI Huang,WU Tuo-jiang,LI Song,CHEN Yang-xi

DOI: https://doi.org/10.3969/j.issn.1673-5749.2008.03.027

2008-01-01

Abstract:Raf kinase inhibitory protein(RKIP) that serve as endogenous modulators of mitogen-activated protein kinase(MAPK) signaling pathway, have been demonstrated to play an increasingly important role in growth and differentiation in organisms. RKIP is a highly conserved, ubiquitously expressed protein. RKIP is identified as playing a role in MAPK cascade, and identification of the mechanism by which it regulates Raf-1 activation.
The Inhibitor Effect of RKIP on Inflammasome Activation and Inflammasome-Dependent Diseases

Qiang Qin,Huan Liu,Jia’nan Shou,Yu Jiang,Hong Yu,Xiaojian Wang

DOI: https://doi.org/10.1038/s41423-020-00525-3

2020-01-01

Cellular and Molecular Immunology

Abstract:Aberrant inflammasome activation contributes to the pathogenesis of various human diseases,including atherosclerosis,gout,and metabolic disorders.Elucidation of the underlying mechanism involved in the negative regulation of the inflammasome is important for developing new therapeutic targets for these diseases.Here,we showed that Raf kinase inhibitor protein(RKIP)negatively regulates the activation of the NLRP1,NLRP3,and NLRC4 inflammasomes.RKIP deficiency enhanced caspase-1 activation and IL-1β secretion via NLRP1,NLRP3,and NLRC4 inflammasome activation in primary macrophages.The overexpression of RKIP in THP-1 cells inhibited NLRP1,NLRP3,and NLRC4 inflammasome activation.RKIP-deficient mice showed increased sensitivity to Alum-induced peritonitis and Salmonella typhimurium-induced inflammation,indicating that RKIP inhibits NLRP3 and NLRC4 inflammasome activation in vivo.Mechanistically,RKIP directly binds to apoptosis-associated speck-like protein containing a caspase-recruitment domain(ASC)and competes with NLRP1,NLRP3,or NLRC4 to interact with ASC,thus interrupting inflammasome assembly and activation.The depletion of RKIP aggravated inflammasome-related diseases such as monosodium urate(MSU)-induced gouty arthritis and high-fat diet(HFD)-induced metabolic disorders.Furthermore,the expression of RKIP was substantially downregulated in patients with gouty arthritis or type 2 diabetes(T2D)compared to healthy controls.Collectively,our findings suggest that RKIP negatively regulates NLRP1,NLRP3,and NLRC4 inflammasome activation and is a potential therapeutic target for the treatment of inflammasome-related diseases.
Raf Kinase Inhibitor Protein Negatively Regulates FcεRI-mediated Mast Cell Activation and Allergic Response.

Wenlong Lin,Fasheng Su,Rahul Gautam,Ning Wang,Yuanyuan Zhang,Xiaojian Wang

DOI: https://doi.org/10.1073/pnas.1805474115

2018-01-01

Abstract:The signaling cascades triggered by the cross-linkage of immunoglobulin E (IgE) with its high-affinity receptor (FcεRI) on mast cells contribute to multiple allergic disorders, such as asthma, rhinitis, and atopic dermatitis. Restraint of intracellular signals for mast cell activation is essential to restore homeostasis. In this study, we found that Raf kinase inhibitor protein (RKIP) negatively regulated mast cell activation. RKIP-deficient mast cells showed greater IgE-FcεRI-mediated activation than wild-type mast cells. Consistently, RKIP deficiency in mast cells rendered mice more sensitive to IgE-FcεRI-mediated allergic responses and ovalbumin-induced airway inflammation. Mechanistically, RKIP interacts with the p85 subunit of PI3K, prevents it from binding to GRB2-associated binding protein 2 (Gab2), and eventually inhibits the activation of the PI3K/Akt/NF-κB complex and its downstream signaling. Furthermore, the expression of RKIP was significantly down-regulated in the peripheral blood of asthma patients and in the IgE-FcεRI-stimulated mast cells. Collectively, our findings not only suggest that RKIP plays an important role in controlling mast cell-mediated allergic responses but also provide insight into therapeutic targets for mast cell-related allergic diseases.
[Research Progress on Receptor Interacting Proteins in Inflammation].

Jingjing Ding,Yunbi Lu

DOI: https://doi.org/10.3785/j.issn.1008-9292.2018.02.13

2018-01-01

Abstract:Receptor interacting proteins (RIPs) are a group of threonine/serine protein kinases, which have relatively conserved kinase domains and different non-kinase domains, and are involved in physiological and pathological processes including innate immune response and inflammation. In recent years, many studies have shown that RIPs mediate cell necroptosis and triggers inflammatory responses by participating in the formation of necrotic complexes, and RIP1 and RIP3 are particularly closely related to cell necrosis. Cell necroptosis is a well-regulated way of cell death. The death signal that transmit through the TNF signaling pathway and the Toll-like receptor signaling pathway can recruit and phosphorylate mixed lineage kinase domain-like protein (MLKL), and eventually leading to disintegration and death of cells, and the release of cells intercellular material after cell disintegration can trigger an inflammatory reaction. This review mainly focuses on the major signaling pathways and molecular mechanisms that are involved in the mediation of necrosis and inflammation by RIPs. It also highlights the importance of RIPs in the development of inflammatory diseases and their potentials as therapeutic targets for inflammatory diseases.
Studies on the Biological Function of Raf Kinase Inhibitor Protein(rkip)

HU Xinzhou,WANG Xu,ZHANG Wei

DOI: https://doi.org/10.3969/j.issn.1004-0374.2007.01.008

2007-01-01

Abstract:Raf kinase inhibitor protein (RKIP) is a member of the phosphatidylethanolamine -binding protein (PEBP) family, which is a widely expressed protein in a variety of different species. It plays a pivotal modulatory role in several intracellular signaling cascades. RKIP binds to Raf-1, and blocks MAPK signaling pathway. Also it has been demonstrated to regulate G-protein-coupled receptor signaling pathway and NF-κB signaling . RKIP plays a critical role in several physiological processes including membrane biosynthesis, spermatogenesis, neural development and apoptosis. It also contributes to pathophysiological processes including Alzheimer’s disease and diabetic nephropathy. Additionally, recent researches show RKIP is a novel metastasis suppressor, which suppresses metastasis in prostate cancer, breast cancer and melanoma cancer. And RKIP becomes a novel prognostic marker in prostate cancer.
RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact

Apostolos Zaravinos,Benjamin Bonavida,Ekaterini Chatzaki,Stavroula Baritaki

DOI: https://doi.org/10.3390/cancers10090287

2018-08-24

Cancers

Abstract:RAF-kinase inhibitor protein (RKIP) is a well-established tumor suppressor that is frequently downregulated in a plethora of solid and hematological malignancies. RKIP exerts antimetastatic and pro-apoptotic properties in cancer cells, via modulation of signaling pathways and gene products involved in tumor survival and spread. Here we review the contribution of RKIP in the regulation of early metastatic steps such as epithelial–mesenchymal transition (EMT), migration, and invasion, as well as in tumor sensitivity to conventional therapeutics and immuno-mediated cytotoxicity. We further provide updated justification for targeting RKIP as a strategy to overcome tumor chemo/immuno-resistance and suppress metastasis, through the use of agents able to modulate RKIP expression in cancer cells.

oncology
The Role of RKIP in the Regulation of EMT in the Tumor Microenvironment

Hannah Cessna,Stavroula Baritaki,Apostolos Zaravinos,Benjamin Bonavida

DOI: https://doi.org/10.3390/cancers14194596

2022-09-23

Cancers

Abstract:The Raf Kinase Inhibitor Protein (RKIP) is a unique gene product that directly inhibits the Raf/Mek/Erk and NF-kB pathways in cancer cells and resulting in the inhibition of cell proliferation, viability, EMT, and metastasis. Additionally, RKIP is involved in the regulation of cancer cell resistance to both chemotherapy and immunotherapy. The low expression of RKIP expression in many cancer types is responsible, in part, for the pathogenesis of cancer and its multiple properties. The inhibition of EMT and metastasis by RKIP led to its classification as a tumor suppressor. However, the mechanism by which RKIP mediates its inhibitory effects on EMT and metastases was not clear. We have proposed that one mechanism involves the negative regulation by RKIP of the expression of various gene products that mediate the mesenchymal phenotype as well as the positive regulation of gene products that mediate the epithelial phenotype via signaling cross talks between RKIP and each gene product. We examined several EMT mesenchymal gene products such as Snail, vimentin, N-cadherin, laminin and EPCAM and epithelial gene products such as E-cadherin and laminin. We have found that indeed these negative and positive correlations were detected in the signaling cross-talks. In addition, we have also examined bioinformatic data sets on different human cancers and the findings corroborated, in large part, the findings observed in the signaling cross-talks with few exceptions in some cancer types. The overall findings support the underlying mechanism by which the tumor suppressor RKIP regulates the expression of gene products involved in EMT and metastasis. Hence, the development of agent that can selectively induce RKIP expression in cancers with low expressions should result in the activation of the pleiotropic anti-cancer activities of RKIP and resulting in multiple effects including inhibition of tumor cell proliferation, EMT, metastasis and sensitization of resistant tumor cells to respond to both chemotherapeutics and immunotherapeutics.

oncology
The Regulatory Role of PINK1 in The Inflammation and Immune Response

Zhao-Ru ZHANG,Jun ZHOU

DOI: https://doi.org/10.13865/j.cnki.cjbmb.2017.12.05

2017-01-01

Abstract:PINK1 (PTEN induced putative kinase 1) is a ubiquitously expressed protein of 581-amino acids that contains a highly conserved serine-threonine kinase domain.It is associated with the mitophagy and the pathogenesis of a familial form of Parkinson's disease.Parkinson's disease is a neurodegenerative disorder of unknown etiology.Research on PINK1 has recently unraveled that it has multiple functions beyond Parkinson's disease,implicating it in a growing number of human pathologies,including tumor,diabetes,cardiopulmonary dysfunctions,et al.Extensive studies have identified PINK1 as a crucial player in regulating the proliferation and differentiation of T cells,inhibiting a novel mitochondrial-derived vesicle (MDV) pathway-mediated mitochondrial antigen presentation (MitAP),as well as in the innate immune response and inflammatory response.In addition,the NLRP3 proteasomePINK1 axis plays an important protective role during hyperoxia-induced endothelial and lung injury.Moreover,recent research also reveals a novel PINK1-dependent neuroimmune pathway that regulates peripheral inflammation via controlling neurotransmitter release,NLRP3 inflammasome activation and inflammasome-dependent cytokine HMGB1 production in a sepsis model.The PINK1-NLRP3-HMGB1 pathway might indicate a novel clinical therapeutic target for future treatment of sepsis and other inflammatory disorders.In this review,we provide a concise overview on the different roles of PINK1 in inflammation and immune response.
RKIP suppresses the influenza A virus‐induced airway inflammatory response via the ERK/MAPK pathway

Jing-Jing Ye,Si-Liang Wei,Yuan-Yuan Wei,Da-Wei Zhang,Li Sun,Hui-Mei Wu,Ji-Long Shen,Li Yu,Yong Wang,Guang-He Fei

DOI: https://doi.org/10.3892/ijmm.2022.5204

IF: 5.314

2022-11-16

International Journal of Molecular Medicine

Abstract:Raf kinase inhibitor protein (RKIP) is an inflammation‑inhibiting mediator that is involved in several diseases; however, the potential mechanism of action of RKIP on the inflammatory response induced by influenza A virus (IAV) remains unclear. The present study aimed to investigate whether RKIP regulated the inflammatory response via the ERK/MAPK pathway. The present study detected the expression levels of RKIP and alterations in the inflammatory response in human normal bronchial epithelial BEAS‑2B cells, diseased human bronchial epithelial cells and primary human bronchial epithelial cells infected with IAV. Cells were treated with locostatin to inhibit the expression of RKIP. RKIP was overexpressed by lentivirus transduction and the small molecule inhibitor SCH772984 was applied to specifically inhibit activation of the ERK/MAPK pathway. In addition, C57BL/6 mice were infected with IAV to further confirm the role of RKIP in regulation of the inflammatory response via ERK/MAPK <i>in vivo</i>. Western blotting, reverse transcription‑quantitative PCR, ELISA, 5‑ethynyl‑-2'‑deoxyuridine assay, immunofluorescence staining, Cell Counting Kit‑8, cell cycle assay, hematoxylin and eosin staining, and immunohistochemistry were used to detect all of the changes. Notably, RKIP attenuated the inflammatory response that was triggered by IAV infection in airway epithelial cells, which was characterized by augmented inflammatory cytokines and cell cycle arrest. Furthermore, the ERK/MAPK pathway was revealed to be activated by IAV infection and downregulation of RKIP aggravated the airway inflammatory response. By contrast, overexpression of RKIP effectively ameliorated the airway inflammatory response induced by IAV. These findings demonstrated that RKIP may serve a protective role in airway epithelial cells by combating inflammation via the ERK/MAPK pathway. Collectively, the present findings suggested that RKIP may negatively regulate airway inflammation and thus may constitute a promising therapeutic strategy for airway inflammatory‑related diseases that are induced by IAV.

medicine, research & experimental
Effect of Raf Kinase Inhibitor Protein Expression on Malignant Biological Behavior and Progression of Colorectal Cancer

Yun Wang,Ling-Yun Wang,Fen Feng,Yang Zhao,Ma-Yan Huang,Qiong Shao,Cui Chen,Hui Sheng,Dong-Liang Chen,Zhao-Lei Zeng,Rui-Hua Xu,Yu-Hong Li

DOI: https://doi.org/10.3892/or.2015.4157

2015-01-01

Oncology Reports

Abstract:The Raf kinase inhibitor protein (RKIP) is a novel metastasis suppressor. RKIP was previously found to have low expression in a colorectal cancer (CRC) patient cohort by immunohistochemistry. However, the role of RKIP in CRC remains undetermined. In the present study, immunohistochemistry was performed to compare RKIP expression between 129 paired stage II CRC and adjacent non-tumorous tissues. The correlations between clinical parameters, prognosis and RKIP expression were evaluated. To investigate the effect of RKIP on proliferation and metastasis, RKIP was overexpressed and knocked down in colon cancer cell lines. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Transwell and wound-healing assays were performed. Murine models were established to confirm the influence of RKIP on malignant tumor phenotypes in vivo. Our results showed that RKIP expression was significantly decreased in the CRC tissues compared to the adjacent non‑cancerous tissues (p<0.001) and was correlated with the risk of relapse in stage II CRC (p<0.05). Overexpression of RKIP suppressed HCT116 cell metastasis in vitro and in vivo, whereas knockdown of RKIP expression in SW480 cells and its murine model increased metastatic ability (p<0.05). No effect of RKIP on cell proliferation in CRC was observed. These data suggest that RKIP is an important metastasis-suppressor gene in CRC. The re-expression of RKIP could be a potential therapeutic target for antimetastatic strategies for CRC.
Signal Transduction And Metastasis Suppression: The Role Of Raf Kinase Inhibitor Protein (Rkip) In Breast Cancer

Zhi Yao,Rong Lu

2010-01-01

Abstract:The development of breast cancer and its spread to other parts of the body requires several changes of signal transduction factors in the cells leading to de-differentiation, uncontrolled proliferation, and invasion. Invasion and metastasis to the other tissues of the body is the final and fatal step during breast cancer progression and is the least understood genetically. Understanding the biology of metastasis suppressors provides valuable mechanistic insights that may translate to therapeutic opportunities. The Raf Icinase inhibitor protein (RKIP) belongs to an evolutionarily conserved family of phosphatidylethanolamine-binding proteins (PEBPs), and was originally identified as the first physiologic inhibitor of Raf/MEK/ERK pathway. RKIP inhibits MAP kinase (Raf-MEK-ERK), G protein-coupled receptor (GPCR) kinase and NE-kappa B signaling cascades. Because RKIP mediates the crosstalk between several important cellular signaling pathways a variety of ablative interventions suggest that reduced RKIP-1 function may influence metastasis, angiogenesis, and resistance to apoptosis. Loss or depletion of RKIP results in disruption of the normal cellular stasis and can lead to chromosomal abnormalities and disease states such as cancer. Studies in cell cultures and animal models have suggested a role of RKIP in suppressing the metastasis spread of breast cancer cells. And there exits correlative evidence of RKIP as a metastasis suppressor in breast cancer patients: RKIP was shown to be expressed in primary human breast tumors but largely absent in matched lymph node metastases. The goal of this chapter is to provide an update and highlight some of the unique features of RKIP that make it a critical player in the regulation of cellular signaling processes, and the meaning of considering RKIP as potential therapeutic targets for the limitation of breast cancer.
Mechanism of Raf Kinase Inhibitor Protein Down-Regulation in Cancer

Wang Yun,Li Yuhong

DOI: https://doi.org/10.3760/cma.j.issn.1673-422x.2015.10.008

2015-01-01

Abstract:Raf kinase inhibiting protein (RKIP)plays a vital role in various physiological processes and participates in multiple signaling pathways,with a close releationgship with tumor.The mechanism of RKIP down-regulation in neoplasms includes transcriptional regulation,methylation,acetylation,histone modifica-tion,microRNA regulation and NF-κB/Snail/RKIP loop regulation.
Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications

Mai Ho,Benjamin Bonavida

DOI: https://doi.org/10.3390/cells13100864

IF: 6

2024-05-17

Cells

Abstract:Innovations in cancer immunotherapy have resulted in the development of several novel immunotherapeutic strategies that can disrupt immunosuppression. One key advancement lies in immune checkpoint inhibitors (ICIs), which have shown significant clinical efficacy and increased survival rates in patients with various therapy-resistant cancers. This immune intervention consists of monoclonal antibodies directed against inhibitory receptors (e.g., PD-1) on cytotoxic CD8 T cells or against corresponding ligands (e.g., PD-L1/PD-L2) overexpressed on cancer cells and other cells in the tumor microenvironment (TME). However, not all cancer cells respond-there are still poor clinical responses, immune-related adverse effects, adaptive resistance, and vulnerability to ICIs in a subset of patients with cancer. This challenge showcases the heterogeneity of cancer, emphasizing the existence of additional immunoregulatory mechanisms in many patients. Therefore, it is essential to investigate PD-L1's interaction with other oncogenic genes and pathways to further advance targeted therapies and address resistance mechanisms. Accordingly, our aim was to investigate the mechanisms governing PD-L1 expression in tumor cells, given its correlation with immune evasion, to uncover novel mechanisms for decreasing PD-L1 expression and restoring anti-tumor immune responses. Numerous studies have demonstrated that the upregulation of Raf Kinase Inhibitor Protein (RKIP) in many cancers contributes to the suppression of key hyperactive pathways observed in malignant cells, alongside its broadening involvement in immune responses and the modulation of the TME. We, therefore, hypothesized that the role of PD-L1 in cancer immune surveillance may be inversely correlated with the low expression level of the tumor suppressor Raf Kinase Inhibitor Protein (RKIP) expression in cancer cells. This hypothesis was investigated and we found several signaling cross-talk pathways between the regulations of both RKIP and PD-L1 expressions. These pathways and regulatory factors include the MAPK and JAK/STAT pathways, GSK3β, cytokines IFN-γ and IL-1β, Sox2, and transcription factors YY1 and NFκB. The pathways that upregulated PD-L1 were inhibitory for RKIP expression and vice versa. Bioinformatic analyses in various human cancers demonstrated the inverse relationship between PD-L1 and RKIP expressions and their prognostic roles. Therefore, we suspect that the direct upregulation of RKIP and/or the use of targeted RKIP inducers in combination with ICIs could result in a more targeted anti-tumor immune response-addressing the therapeutic challenges related to PD-1/PD-L1 monotherapy alone.
The roles and mechanisms of RKIP in the invasion and metastasis of nasopharyngeal carcinoma

Yuanyuan WANG,Qiuyan HE,Hongmei YI,Zhiqiang XIAO

DOI: https://doi.org/10.3978/j.issn.2095-6959.2015.03.010

2015-01-01

Abstract:Objective: To investigate the roles and mechanisms of Raf kinase inhibitory protein (RKIP) in the invasion and metastasis of nasopharyngeal carcinoma (NPC).Methods: Immunohistochemistry was performed to detect the expression levels of RKIP in the NPC tissue specimens with different metastasis; Establishment of stable transfected NPC cell lines with RKIP expression changes using lipofectamine 2000; Scratch wound-wealing assay and traswell invasion assay were performed to determine the ability of cell migration and invasion; Western blot was used to detect the phosphorylated levels of NF-κB signaling molecules in NPC cells.Results: RKIP expression was signiifcantly reduced in the NPCs relative to normal nasopharyngeal mucosa, and in the NPCs with metastasis relative to NPCs without metastasis, and there was not PKIP expression in the almost all lymphonode metastases. RKIP expression was found to be significantly associated with lymph node and distant metastasis, advanced clinical stage and reduced overall survival. Stable overexpression of RKIP in 5-8F NPC cells dramatically decreased tumor cell migration and invasion, whereas stable knockdown of RKIP in 6-10B NPC cells signiifcantly increased tumor cell migration and invasion. RKIP expression levels were negatively associated with the activity of NF-κB signaling pathway, and Bay11-7082 could inhibit the migration and invasion of 6-10B cells with RKIP knockdown.Conclusion:RKIP may be a metastatic suppressor protein of NPC, NPC patients with low RKIP level had a poor prognosis, and RKIP downregulation promoted NPC invasion and metastasis by activating NF-κB signaling pathway.
Progresses in the structure and biological function of Raf kinase inhibitory protein

WU Zhi-Hua,GUO Chen-Yun

DOI: https://doi.org/10.13376/j.cbls/2013.07.014

2013-01-01

Abstract:Raf kinase inhibitory protein(RKIP) is a member of the phosphatidylethanolamine-binding protein(PEBP) superfamily,which plays vital roles in many physiological processes and regulates MAPK,GPCR and NFκB signaling pathways.Abnormal signaling pathways will promote tumorigenesis and development.It has been reported that RKIP modulates tumors at several stages including tumorigenesis,development,metastasis and therapeutic response.By now RKIP has been considered as a new biomarker for cancer diagnosis.Therefore,it is highly significant to study the structure and function of RKIP,which helps us understand the structural basis and the molecular mechanism of RKIP-modulated signal pathways,and facilitate the drug development against diseases caused by abnormal signal transduction.This article reviewed the structural characteristics,biological functions of RKIP and its relationship with tumor.
Insights of RKIP-Derived Suppression of Prostate Cancer

Ying Dong,Xiaozeng Lin,Anil Kapoor,Yan Gu,Hui Xu,Pierre Major,Damu Tang

DOI: https://doi.org/10.3390/cancers13246388

2021-01-01

Cancers

Abstract:Prostate cancer (PC) is a major cause of cancer death in men. The disease has a great disparity in prognosis. Although low grade PCs with Gleason scores ≤ 6 are indolent, high-risk PCs are likely to relapse and metastasize. The standard of care for metastatic PC (mPC) remains androgen deprivation therapy (ADT). Resistance commonly occurs in the form of castration resistant PC (CRPC). Despite decades of research efforts, CRPC remains lethal. Understanding of mechanisms underpinning metastatic progression represents the overarching challenge in PC research. This progression is regulated by complex mechanisms, including those regulating PC cell proliferation, epithelial–mesenchymal transition (EMT), and androgen receptor (AR) signaling. Among this PC metastatic network lies an intriguing suppressor of PC metastasis: the Raf kinase inhibitory protein (RKIP). Clinically, the RKIP protein is downregulated in PC, and showed further reduction in mPC. In xenograft mouse models for PC, RKIP inhibits metastasis. In vitro, RKIP reduces PC cell invasion and sensitizes PC cells to therapeutic treatments. Mechanistically, RKIP suppresses Raf-MEK-ERK activation and EMT, and modulates extracellular matrix. In return, Snail, NFκB, and the polycomb protein EZH2 contribute to inhibition of RKIP expression. In this review, we will thoroughly analyze RKIP’s tumor suppression actions in PC.
Reduced Expression of Raf Kinase Inhibitor Protein Correlates with Poor Prognosis in Pancreatic Cancer

Shi-peng Song,Sheng-bin Zhang,Zhe-hai Li,Yong-sheng Zhou,Bing Li,Zhan-wei Bian,Qian-de Liao,Yang-de Zhang

DOI: https://doi.org/10.1007/s12094-012-0870-7

2012-01-01

Clinical & Translational Oncology

Abstract:Raf kinase inhibitory protein (RKIP) is an inhibitor of the Raf/MEK/MAP kinase signaling cascade and a suppressor of cancer metastasis. But its function in pancreatic cancer was not yet clarified completely. The aim of this study was to investigate the involvement of RKIP in pancreatic cancer.

Role of RKIP in Inflammatory Responses

Rkip Mediates Autoimmune Inflammation By Positively Regulating Il-17r Signaling

Raf Kinase Inhibitor Protein Preferentially Promotes Tlr3-Triggered Signaling and Inflammation

Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice

Regulation role of Raf kinase inhibitory protein to mitogen-activated protein kinase signaling pathway

The Inhibitor Effect of RKIP on Inflammasome Activation and Inflammasome-Dependent Diseases

Raf Kinase Inhibitor Protein Negatively Regulates FcεRI-mediated Mast Cell Activation and Allergic Response.

[Research Progress on Receptor Interacting Proteins in Inflammation].

Studies on the Biological Function of Raf Kinase Inhibitor Protein(rkip)

RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact

The Role of RKIP in the Regulation of EMT in the Tumor Microenvironment

The Regulatory Role of PINK1 in The Inflammation and Immune Response

RKIP suppresses the influenza A virus‐induced airway inflammatory response via the ERK/MAPK pathway

Effect of Raf Kinase Inhibitor Protein Expression on Malignant Biological Behavior and Progression of Colorectal Cancer

Signal Transduction And Metastasis Suppression: The Role Of Raf Kinase Inhibitor Protein (Rkip) In Breast Cancer

Mechanism of Raf Kinase Inhibitor Protein Down-Regulation in Cancer

Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications

The roles and mechanisms of RKIP in the invasion and metastasis of nasopharyngeal carcinoma

Progresses in the structure and biological function of Raf kinase inhibitory protein

Insights of RKIP-Derived Suppression of Prostate Cancer

Reduced Expression of Raf Kinase Inhibitor Protein Correlates with Poor Prognosis in Pancreatic Cancer